News Sanofi passes on Alnylam's breakthrough therapy Alnylam is to forge ahead with a rare disease therapy on its own after Sanofi decided to opt out of a co-development and co-marketing deal.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
